MAP2K7 and lung carcinoma: These results provide a strong therapeutic rationale to treat epithelial KRAS-mutant lung cancer with ERBB and MEK inhibitors, and mesenchymal-like KRAS-mutant lung cancer by combined therapy with FGFR and MEK inhibitors [3, 89].